Literature DB >> 25177262

AGO Recommendations for the Diagnosis and Treatment of Patients with Advanced and Metastatic Breast Cancer: Update 2014.

Volker Hanf1, Florian Schütz2, Cornelia Liedtke3, Marc Thill4.   

Abstract

Entities:  

Keywords:  Guidelines; Locoregional relapse; Metastatic breast cancer; Targeted therapy

Year:  2014        PMID： 25177262      PMCID： PMC4132248          DOI： 10.1159/000363551

Source DB:  PubMed          Journal:  Breast Care (Basel)        ISSN： 1661-3791            Impact factor:   2.860


× No keyword cloud information.
  46 in total

1.  Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer.

Authors:  José Baselga; Mario Campone; Martine Piccart; Howard A Burris; Hope S Rugo; Tarek Sahmoud; Shinzaburo Noguchi; Michael Gnant; Kathleen I Pritchard; Fabienne Lebrun; J Thaddeus Beck; Yoshinori Ito; Denise Yardley; Ines Deleu; Alejandra Perez; Thomas Bachelot; Luc Vittori; Zhiying Xu; Pabak Mukhopadhyay; David Lebwohl; Gabriel N Hortobagyi
Journal:  N Engl J Med       Date:  2011-12-07       Impact factor: 91.245

2.  Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study.

Authors:  Brian Leyland-Jones; Vladimir Semiglazov; Marek Pawlicki; Tadeusz Pienkowski; Sergei Tjulandin; George Manikhas; Antoly Makhson; Anton Roth; David Dodwell; Jose Baselga; Mikhail Biakhov; Konstantinas Valuckas; Edouard Voznyi; Xiangyang Liu; Els Vercammen
Journal:  J Clin Oncol       Date:  2005-08-08       Impact factor: 44.544

3.  Trastuzumab emtansine for HER2-positive advanced breast cancer.

Authors:  Sunil Verma; David Miles; Luca Gianni; Ian E Krop; Manfred Welslau; José Baselga; Mark Pegram; Do-Youn Oh; Véronique Diéras; Ellie Guardino; Liang Fang; Michael W Lu; Steven Olsen; Kim Blackwell
Journal:  N Engl J Med       Date:  2012-10-01       Impact factor: 91.245

4.  Symptomatic bone marrow involvement in breast cancer--clinical presentation, treatment, and prognosis: a single institution review of 22 cases.

Authors:  Hans-Georg Kopp; Katja Krauss; Tanja Fehm; Annette Staebler; Jennifer Zahm; Wichard Vogel; Lothar Kanz; Frank Mayer
Journal:  Anticancer Res       Date:  2011-11       Impact factor: 2.480

Review 5.  Whole brain radiotherapy for the treatment of newly diagnosed multiple brain metastases.

Authors:  May N Tsao; Nancy Lloyd; Rebecca K S Wong; Edward Chow; Eileen Rakovitch; Normand Laperriere; Wei Xu; Arjun Sahgal
Journal:  Cochrane Database Syst Rev       Date:  2012-04-18

6.  Aprepitant versus dexamethasone for preventing chemotherapy-induced delayed emesis in patients with breast cancer: a randomized double-blind study.

Authors:  Fausto Roila; Benedetta Ruggeri; Enzo Ballatori; Albano Del Favero; Maurizio Tonato
Journal:  J Clin Oncol       Date:  2013-12-09       Impact factor: 44.544

Review 7.  Thermal ablation therapies in patients with breast cancer liver metastases: a review.

Authors:  Thomas J Vogl; Parviz Farshid; Nagy N N Naguib; Stephan Zangos
Journal:  Eur Radiol       Date:  2012-10-13       Impact factor: 5.315

8.  Cardiac tolerability of pertuzumab plus trastuzumab plus docetaxel in patients with HER2-positive metastatic breast cancer in CLEOPATRA: a randomized, double-blind, placebo-controlled phase III study.

Authors:  Sandra M Swain; Michael S Ewer; Javier Cortés; Dino Amadori; David Miles; Adam Knott; Emma Clark; Mark C Benyunes; Graham Ross; José Baselga
Journal:  Oncologist       Date:  2013-03-08

Review 9.  Benefits and harms of erythropoiesis-stimulating agents for anemia related to cancer: a meta-analysis.

Authors:  Marcello Tonelli; Brenda Hemmelgarn; Tony Reiman; Braden Manns; M Neil Reaume; Anita Lloyd; Natasha Wiebe; Scott Klarenbach
Journal:  CMAJ       Date:  2009-04-30       Impact factor: 8.262

10.  Definitive results of a phase III adjuvant trial comparing three chemotherapy regimens in women with operable, node-positive breast cancer: the NSABP B-38 trial.

Authors:  Sandra M Swain; Gong Tang; Charles E Geyer; Priya Rastogi; James N Atkins; Paul P Donnellan; Louis Fehrenbacher; Catherine A Azar; André Robidoux; Jonathan A Polikoff; Adam M Brufsky; David D Biggs; Edward A Levine; John L Zapas; Louise Provencher; Donald W Northfelt; Soonmyung Paik; Joseph P Costantino; Eleftherios P Mamounas; Norman Wolmark
Journal:  J Clin Oncol       Date:  2013-08-12       Impact factor: 44.544
View more
  5 in total

Review 1.  Role of Hyperthermia in Breast Cancer Locoregional Recurrence: A Review.

Authors:  Sergio Maluta; Merel Willemijn Kolff
Journal:  Breast Care (Basel)       Date:  2015-10-16       Impact factor: 2.860

Review 2.  Targeted Therapies in HER2-Positive Breast Cancer - a Systematic Review.

Authors:  Amelie Schramm; Nikolaus De Gregorio; Peter Widschwendter; Visnja Fink; Jens Huober
Journal:  Breast Care (Basel)       Date:  2015-06-18       Impact factor: 2.860

3.  Circulating Tumour Cells, Circulating Tumour DNA and Circulating MicroRNA in Metastatic Breast Carcinoma - What is the Role of Liquid Biopsy in Breast Cancer?

Authors:  Arkadius Polasik; Marie Tzschaschel; Fabienne Schochter; Amelie de Gregorio; Thomas W P Friedl; Brigitte Rack; Andreas Hartkopf; Peter A Fasching; Andreas Schneeweiss; Volkmar Müller; Jens Huober; Wolfgang Janni; Tanja Fehm
Journal:  Geburtshilfe Frauenheilkd       Date:  2017-12-18       Impact factor: 2.915

4.  A randomized phase III study evaluating pegylated liposomal doxorubicin versus capecitabine as first-line therapy for metastatic breast cancer: results of the PELICAN study.

Authors:  Nadia Harbeck; Steffen Saupe; Elke Jäger; Marcus Schmidt; Rolf Kreienberg; Lothar Müller; Burkhard Joerg Otremba; Dirk Waldenmaier; Julia Dorn; Mathias Warm; Michael Scholz; Michael Untch; Maike de Wit; Jana Barinoff; Hans-Joachim Lück; Philipp Harter; Doris Augustin; Paul Harnett; Matthias W Beckmann; Salah-Eddin Al-Batran
Journal:  Breast Cancer Res Treat       Date:  2016-10-31       Impact factor: 4.872

5.  Circulating uPA as a potential prognostic biomarker for resectable esophageal squamous cell carcinoma.

Authors:  Xiao He; Xiaoling Xu; Guanxia Zhu; Hong Ye
Journal:  Medicine (Baltimore)       Date:  2019-03       Impact factor: 1.889
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.